Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Jan 8

PMID 39771535

Authors

Mingqin Shi

Xinyao Li

Liwei Xing

Zhenmin Li

Sitong Zhou

Zihui Wang

Xuelian Zou

Yuqing She

Rong Zhao

Dongdong Qin

Affiliations

Soon will be listed here.

Abstract

Polycystic ovary syndrome (PCOS) is the predominant endocrine disorder among women of reproductive age and represents the leading cause of anovulatory infertility, which imposes a considerable health and economic burden. Currently, medications used to treat PCOS can lead to certain adverse reactions, such as affecting fertility and increasing the risk of venous thrombosis. Drug delivery systems utilizing nanomaterials, characterized by prolonged half-life, precision-targeted delivery, enhanced bioavailability, and reduced toxicity, are currently being employed in the management of PCOS. This innovative approach is gaining traction as a favored strategy for augmenting the therapeutic efficacy of medications. Consequently, this paper discusses the roles of nanoparticles, nanocarriers, and targeted ligands within nanomaterial-based drug delivery systems, aiming to identify optimal methodologies for treating PCOS using nanomaterials. Additionally, prospective research avenues concerning nanomaterial-based delivery systems in the context of PCOS, as well as the implications of existing insights on the advancement of novel therapies for PCOS, are highlighted.

References

Melin J, Forslund M, Alesi S, Piltonen T, Romualdi D, Spritzer P . The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Eur J Endocrinol. 2023; 189(2):S37-S63. DOI: 10.1093/ejendo/lvad098. View

Yan S, Gao Z, Ding J, Chen S, Wang Z, Jin W . Nanocomposites based on nanoceria regulate the immune microenvironment for the treatment of polycystic ovary syndrome. J Nanobiotechnology. 2023; 21(1):412. PMC: 10631133. DOI: 10.1186/s12951-023-02182-w. View

Kyritsi E, Dimitriadis G, Kyrou I, Kaltsas G, Randeva H . PCOS remains a diagnosis of exclusion: a concise review of key endocrinopathies to exclude. Clin Endocrinol (Oxf). 2016; 86(1):1-6. DOI: 10.1111/cen.13245. View

Faramarzi L, Dadashpour M, Sadeghzadeh H, Mahdavi M, Zarghami N . Enhanced anti-proliferative and pro-apoptotic effects of metformin encapsulated PLGA-PEG nanoparticles on SKOV3 human ovarian carcinoma cells. Artif Cells Nanomed Biotechnol. 2019; 47(1):737-746. DOI: 10.1080/21691401.2019.1573737. View

Jozkowiak M, Kobylarek D, Bryja A, Gogola-Mruk J, Czajkowski M, Skupin-Mrugalska P . Steroidogenic activity of liposomal methylated resveratrol analog 3,4,5,4'-tetramethoxystilbene (DMU-212) in human luteinized granulosa cells in a primary three-dimensional in vitro model. Endocrine. 2023; 82(3):681-694. PMC: 10618382. DOI: 10.1007/s12020-023-03458-9. View

Gu D, Tung T, Jiesisibieke Z, Chien C, Liu W . Safety of Cinnamon: An Umbrella Review of Meta-Analyses and Systematic Reviews of Randomized Clinical Trials. Front Pharmacol. 2022; 12:790901. PMC: 8804376. DOI: 10.3389/fphar.2021.790901. View

Ndayishimiye J, Kumeria T, Popat A, Falconer J, Blaskovich M . Nanomaterials: The New Antimicrobial Magic Bullet. ACS Infect Dis. 2022; 8(4):693-712. DOI: 10.1021/acsinfecdis.1c00660. View

Nelson-Degrave V, Wickenheisser J, Hendricks K, Asano T, Fujishiro M, Legro R . Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol. 2004; 19(2):379-90. DOI: 10.1210/me.2004-0178. View

Dou L, Zheng Y, Li L, Gui X, Chen Y, Yu M . The effect of cinnamon on polycystic ovary syndrome in a mouse model. Reprod Biol Endocrinol. 2018; 16(1):99. PMC: 6194596. DOI: 10.1186/s12958-018-0418-y. View

10.

Wang Y, Pi C, Feng X, Hou Y, Zhao L, Wei Y . The Influence of Nanoparticle Properties on Oral Bioavailability of Drugs. Int J Nanomedicine. 2020; 15:6295-6310. PMC: 7455773. DOI: 10.2147/IJN.S257269. View

11.

Liao B, Qi X, Yun C, Qiao J, Pang Y . Effects of Androgen Excess-Related Metabolic Disturbances on Granulosa Cell Function and Follicular Development. Front Endocrinol (Lausanne). 2022; 13:815968. PMC: 8883052. DOI: 10.3389/fendo.2022.815968. View

12.

de-Medeiros S, Yamamoto M, de-Medeiros M, Barbosa J, Norman R . Should Subclinical Hypothyroidism Be an Exclusion Criterion for the Diagnosis of Polycystic Ovary Syndrome?. J Reprod Infertil. 2017; 18(2):242-250. PMC: 5565908. View

13.

Armanini D, Andrisani A, Bordin L, Sabbadin C . Spironolactone in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother. 2016; 17(13):1713-5. DOI: 10.1080/14656566.2016.1215430. View

14.

Abdallah A, El-Ghannam M, Hasan A, Mohammad L, Mesalam N, Alsayed R . Selenium Nanoparticles Modulate Steroidogenesis-Related Genes and Improve Ovarian Functions via Regulating Androgen Receptors Expression in Polycystic Ovary Syndrome Rat Model. Biol Trace Elem Res. 2023; 201(12):5721-5733. PMC: 10620277. DOI: 10.1007/s12011-023-03616-0. View

15.

Tang J, Ouyang Q, Li Y, Zhang P, Jin W, Qu S . Nanomaterials for Delivering Antibiotics in the Therapy of Pneumonia. Int J Mol Sci. 2022; 23(24). PMC: 9779065. DOI: 10.3390/ijms232415738. View

16.

Johnson J, Daley D, Tarta C, Stanciu P . Risk of endometrial cancer in patients with polycystic ovarian syndrome: A meta‑analysis. Oncol Lett. 2023; 25(4):168. PMC: 10028221. DOI: 10.3892/ol.2023.13754. View

17.

Lewis M, Kasper J, Bazil J, Frisbee J, Wiseman R . Quantification of Mitochondrial Oxidative Phosphorylation in Metabolic Disease: Application to Type 2 Diabetes. Int J Mol Sci. 2019; 20(21). PMC: 6862501. DOI: 10.3390/ijms20215271. View

18.

Xing L, Xu J, Wei Y, Chen Y, Zhuang H, Tang W . Depression in polycystic ovary syndrome: Focusing on pathogenesis and treatment. Front Psychiatry. 2022; 13:1001484. PMC: 9470949. DOI: 10.3389/fpsyt.2022.1001484. View

19.

Mills G, Badeghiesh A, Suarthana E, Baghlaf H, Dahan M . Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies. Hum Reprod. 2020; 35(7):1666-1674. DOI: 10.1093/humrep/deaa099. View

20.

Burger H . Androgen production in women. Fertil Steril. 2002; 77 Suppl 4:S3-5. DOI: 10.1016/s0015-0282(02)02985-0. View